Alligator Bioscience AB (publ) Interim Report January-March 2019

STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March

    --  First patient dosed in Phase I clinical study of ATOR-1015.
    --  New preclinical data presented demonstrating strong anti-tumor effects
        for the 4-1BB antibody ATOR-1017.
    --  Alligator Bioscience launched RUBY(TM), a novel concept in bispecific
        antibody formats.

Events after the end of the period

    --  Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.
    --  New preclinical data for ATOR-1144 demonstrates potential for activation
        of both the innate and the adaptive immune system as well as direct
        anti-tumor effects.

Financial information

January-March 2019

    --  Net sales, SEK 0.0 million (0.8)
0. Total operating costs SEK -46.7 million (-45.0) 1. Operating result, SEK -46.2 million (-44.0) 2. Earnings per share before and after dilution, SEK -0.62 (-0.59) 3. Cash flow for the period, SEK -34.3 million (0.8) 4. Cash and cash equivalents, including securities, SEK 402.9 million (436.4)

"This is a very exciting year for Alligator. We currently have two projects - ADC-1013 and ATOR-1015 - in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.

Read the complete report in the pdf below.

The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.

For further information, please contact:

Per Norlén

Per-Olof Schrewelius

Cecilia Hofvander
Director IR & Communications

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

This information was brought to you by Cision,c2789720

The following files are available for download:

  Alligator Bioscience AB
                                                              (publ) Interim report
                                                              January-March 2019

View original content:

SOURCE Alligator Bioscience